A promising strategy for overcoming MDR in tumor by magnetic iron oxide nanoparticles co-loaded with daunorubicin and 5-bromotetrandrin
Authors:
Open Access
- 1 September 2011
- journal article
- Published by Taylor & Francis in International Journal of Nanomedicine
- Vol. 6, 2123-31
Abstract
Peer reviewed article authored by (Cheng J, Wang J, Chen BA, Xia GH, Cai XH, Liu R, Ren YY, Bao W, Wang XM). Read article or submit your manuscript for publishing.Keywords
This publication has 29 references indexed in Scilit:
- Effect of magnetic nanoparticles of Fe3O4 and 5-bromotetrandrine on reversal of multidrug resistance in K562/A02 leukemic cellsInternational Journal of Nanomedicine, 2009
- A Phase I Study of the P-Glycoprotein Antagonist Tariquidar in Combination with VinorelbineClinical Cancer Research, 2009
- Inhibition of P-glycoprotein-mediated docetaxel efflux sensitizes ovarian cancer cells to concomitant docetaxel and SN-38 exposureAnti-Cancer Drugs, 2009
- Reversal of multidrug resistance by magnetic Fe3O4 nanoparticle copolymerizating daunorubicin and 5-bromotetrandrine in xenograft nude-miceInternational Journal of Nanomedicine, 2009
- A randomized, placebo-controlled, double-blind phase 2 study of docetaxel compared to docetaxel plus zosuquidar (LY335979) in women with metastatic or locally recurrent breast cancer who have received one prior chemotherapy regimenCancer Chemotherapy and Pharmacology, 2009
- Optimal Design and Characterization of Superparamagnetic Iron Oxide Nanoparticles Coated with Polyvinyl Alcohol for Targeted Delivery and ImagingThe Journal of Physical Chemistry B, 2008
- Nanotechnology platforms and physiological challenges for cancer therapeuticsNanomedicine: Nanotechnology, Biology and Medicine, 2007
- Tetrandrine achieved plasma concentrations capable of reversing MDR in vitro and had no apparent effect on doxorubicin pharmacokinetics in miceCancer Chemotherapy and Pharmacology, 2007
- Exploiting the enhanced permeability and retention effect for tumor targetingDrug Discovery Today, 2006
- Targeting multidrug resistance in cancerNature Reviews Drug Discovery, 2006